Atsuo Maemoto

Atsuo Maemoto is an expert in Gastroenterology at Sapporo Higashi Tokushukai Hospital (Japan). As of July 2026, ScienceLeadR ranks Atsuo Maemoto in the top 1% of experts worldwide for Gastroenteritis. Atsuo Maemoto has authored 85 publications, the most recent in 2026, and is an investigator in 5 clinical trials, 2 of them ongoing. SLR score: 282 (community average: 125). How the SLR is computed.

Gastroenterology

Subspecialties: Hepatology - Public Health - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on July 3, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2012 - 2026

Source: PubMed

Sapporo Higashi Tokushukai Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 85

Citations

Citations: 1 270 1st author: 2 Last author: 6 Unique author: 1

Main journals

Best Journals

Lancet Gastroenterol Hepatol 2

N Engl J Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year
Long-term drug persistence and clinical outcomes of ustekinumab in Crohn's disease: a multicenter real-world study from the Hokkaido phoenix cohort. PMID 42389006 — ustekinumab, fistula, safety, crohn disease, pharmaceutical preparations, drug-related side effects and adverse reactions	Crohns Colitis 360	2026
Short- and Long-Term Effectiveness and Safety of Vedolizumab in Crohn's Disease: A Multicenter Retrospective Study from the Hokkaido Phoenix Cohort. PMID 42376456 — safety, crohn disease, retrospective studies, sex, therapeutics	Inflamm Intest Dis	2026
Long-term treatment outcomes of upadacitinib for Crohn's disease: a single-center retrospective study. PMID 42293308 — fistula, crohn disease, retrospective studies, therapeutics	Crohns Colitis 360	2026
Clinicopathological features and cancer-specific survival in young patients with ulcerative colitis-associated colorectal neoplasia: a nationwide cohort study in Japan. PMID 42154979 — colitis, crohn disease, neoplasms, cohort studies, inflammatory bowel diseases, carcinogenesis, colorectal neoplasms, colitis, ulcerative	Inflamm Bowel Dis	2026
Utility of Hybrid Endoscopy Combining Small-Bowel Capsule Endoscopy and Conventional Ileocolonoscopy in Crohn's Disease. PMID 41736957 — crohn disease, capsule endoscopy, capsules, endoscopy, therapeutics	DEN Open	2026

Clinical Studies 5

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 2 2

Phase 2/Phase 3 2

Phase 3 1

By status:

Active not recruiting 2

Recruiting 2

Completed 1

By type:

Interventional 5

By Monocentric/Multicentric:

monocentric 0

multicentric2to4 0

multicentric5to9 0

multicentricup10 5

Main Topics

Digestive System Diseases 5

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis NCT06598943 — interleukin-23, anti-inflammatory agents, colitis, digestive system diseases, colonic diseases, interleukin-23 subunit p19, inflammatory bowel diseases, intestinal diseases, therapeutics, digestive system, gastrointestinal diseases, ligands, colitis, ulcerative	Phase 2	Active not recruiting	2024
A Phase 2 Study to Evaluate MORF 057 in Adults With Moderately to Severely Active Crohn s Disease NCT06226883 — integrins, safety, crohn disease, inflammatory bowel diseases, small molecules	Phase 2	Recruiting	2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice